Unknown

Dataset Information

The development of potential antibody-based therapies for myeloma.


ABSTRACT: With optimal target antigen selection antibody-based therapeutics can be very effective agents for hematologic malignancies, but none have yet been approved for myeloma. Rituximab and brentuximab vedotin are examples of success for the naked antibody and antibody-drug conjugate classes, respectively. Plasma cell myeloma is an attractive disease for antibody-based targeting due to target cell accessibility and the complementary mechanism of action with approved therapies. Initial antibodies tested in myeloma were disappointing. However, recent results from targeting well-characterized antigens have been more encouraging. In particular, the CD38 and CD138 targeted therapies are showing single-agent activity in early phase clinical trials. Here we will review the development pipeline for nake

SUBMITTER: Sherbenou DW 

PROVIDER: S-EPMC4482758 | biostudies-literature | 2015 Mar

REPOSITORIES: biostudies-literature